Compare AXG & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXG | EVMN |
|---|---|---|
| Founded | 2021 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.2M | 892.4M |
| IPO Year | N/A | N/A |
| Metric | AXG | EVMN |
|---|---|---|
| Price | $3.54 | $23.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $43.29 |
| AVG Volume (30 Days) | ★ 284.8K | 267.7K |
| Earning Date | 01-09-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.53 | N/A |
| Revenue Next Year | $54.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.69 | $13.89 |
| 52 Week High | $4.75 | $33.20 |
| Indicator | AXG | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 47.93 |
| Support Level | $3.49 | $21.40 |
| Resistance Level | $3.82 | $33.20 |
| Average True Range (ATR) | 0.14 | 2.07 |
| MACD | -0.01 | -0.30 |
| Stochastic Oscillator | 30.65 | 40.08 |
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.